In NPC's comments on the International Pricing Index Model for Medicare Part B Drugs, we identify critical methodological limitations associated with the IPI Model, which ultimately undermine the agency’s goal of prioritizing value and improved patient outcomes, over utilization and sickness.

NPC and Discern Health will host a webinar on Feb. 28 from 2 p.m.-3:30 p.m.featuring an expert panel of stakeholders led by Drs. Mark McClellan, Director, Duke-Margolis Center for Health Policy, and Ethan Basch, Director, Cancer Outcomes Research Program, UNC Lineberger Comprehensive Cancer Center, to discuss action steps for better incorporating the patient voice in value-based care.

In his latest column in Specialty Pharmacy Times, NPC President and Chief Executive Officer Dan Leonard explains that rather than trying to score news headlines, what we need is a thoughtful, research-based approach to tackle the health care challenges ahead of us.